<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744131</url>
  </required_header>
  <id_info>
    <org_study_id>OCP-MET-2016</org_study_id>
    <nct_id>NCT02744131</nct_id>
  </id_info>
  <brief_title>OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women</brief_title>
  <acronym>OCP</acronym>
  <official_title>OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kar Clinic &amp; Hospital Pvt. Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nova IVI Fertility, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Patil's Fertility &amp; Endoscopy Clinic, Bangalore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shreyas Hospital &amp; Sushrut Assisted Conception Clinic, Kolhapur</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kar Clinic &amp; Hospital Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To assess effectiveness of ISD (Insulin sensitizing drugs) Vs OCP (Combined E&amp;P
      cyproterone acetate) in improving clinical, hormonal and metabolic features of PCOS(
      polycystic ovary syndrome)women from India.

      Intervention:

      Randomized to receive Metformin 1500 mg / day OR OCP (EE+CA) Life style advice to women with
      BMI ( body mass index) more than 28 , in both groups (PS: progesterone can be added for
      getting withdrawal bleeding for amenorrhoea of more than two months, or for prolonged
      menstrual bleeding. ) Study period: 6 months Clinical evaluation points and tests at
      enrollment and again after 6 month. Clinical: BMI, Waist circumference, Hip circumference,
      Acne score, FG (modified Ferriman Gallwey score ) (after no epilation for last 6 weeks),
      Menstrual History Biochemical: Thyroid function tests, Prolactin,Total Testosterone, Lipid
      Profile, FAsting blood sugar &amp; 75 gm 2 hr Glucose tolerance test (GTT), Sr Insulin, 25-
      hydroxy vitamin D (optional), (Only Radioimmunoassay / Chemiluminescence assays)

      Acronyms: OCP(oral contraceptive pills); PCOS (polycystic ovary syndrome); FBS(fasting blood
      sugar); GTT(glucose tolerance test)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvements in Menstrual cycle in women with polycystic ovary syndrome.</measure>
    <time_frame>Six months</time_frame>
    <description>To compare improvement in Menstrual cycle. Women will be required to maintain a menstrual calendar for the duration of the study and asked to fill a questionnaire before and after study duration.The questionnaire will cover menstrual cycle dates, duration and amount. Interpreting the answered will help in assessing improvement in menstrual pattern.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in hirsutism</measure>
    <time_frame>six months</time_frame>
    <description>FG scores before and after treatment will be compared between the two arms. Modified Ferriman and Gallwey visual score will be used by a nurse to assess before and after the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in acne score</measure>
    <time_frame>Six months</time_frame>
    <description>Acne scores before and after treatment will be compared between the two arms. Visual assessment of acne using &quot;mild/moderate/severe &quot; grades will be assessed before and after study by a physician.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight loss following treatment</measure>
    <time_frame>6months</time_frame>
    <description>Weight loss will be compared between the two arms following 6 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in total testosterones</measure>
    <time_frame>6months</time_frame>
    <description>Reduction in total testosterones, signifying biochemical hyperandrogenemia, will be compared between the two groups following 6 months treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in serum fasting insulin</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction in insulin levels following treatment will be compared between the two arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvements in lipid profile</measure>
    <time_frame>6months</time_frame>
    <description>Any improvement in triglycerides and HDLc (high density lipoprotein c) will be compared between the two groups after 6 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in glucose tolerance</measure>
    <time_frame>6months</time_frame>
    <description>75grams 2 hour glucose challenge test results will be compared pre and post treatment between the two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>OCP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: oral contraceptive pill, combination pill of ethyl estradiol 20 micro gram with Cyproterone acetate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Metformin . Oral insulin sensitising drug in the dose of 1500gms daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate</intervention_name>
    <arm_group_label>OCP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1500mgs per day</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS Women diagnosed by Rotterdam criteria

          -  Age &gt; 16 or menarche of at least 2 yr upto age 40.

          -  Diagnosed by Rotterdam Anovulation F.G. Score ≥ 8 or Total testosterone ≥ 40 ngms/dl
             ovarian volume ≥ 10 cc BMI&gt;23

          -  Women not attempting pregnancy at present.

        Exclusion Criteria:

          -  PCOS Women with BMI ≤ 23

          -  Undergoing any treatment for acne hirsutism. Including Homeopathic, Ayurvedic

          -  Known diabetic or hypertension .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sujata Kar, MD</last_name>
    <phone>919437824163</phone>
    <email>suju2463@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KAR clinic and hospital pvt ltd</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujata Kar, M.D</last_name>
      <phone>+919437824163</phone>
      <email>suju2463@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Suneeta Panigrahi, B.A</last_name>
      <email>womenwing@karhospitals.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial. J Hum Reprod Sci. 2012 Sep;5(3):262-5. doi: 10.4103/0974-1208.106338.</citation>
    <PMID>23531705</PMID>
  </reference>
  <reference>
    <citation>Kar S, Sanchita S. Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: A randomized controlled trial. J Hum Reprod Sci. 2015 Oct-Dec;8(4):197-201. doi: 10.4103/0974-1208.170373.</citation>
    <PMID>26752854</PMID>
  </reference>
  <reference>
    <citation>Kumar P, Nawani N, Malhotra N, Malhotra J, Patil M, Jayakrishnan K, Kar S, Jirge PR, Mahajan N. Assisted reproduction in polycystic ovarian disease: A multicentric trial in India. J Hum Reprod Sci. 2013 Jan;6(1):49-53. doi: 10.4103/0974-1208.112382.</citation>
    <PMID>23869152</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Metformin</keyword>
  <keyword>OCP</keyword>
  <keyword>metabolic parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

